Ignite Creation Date:
2024-05-05 @ 5:32 PM
Last Modification Date:
2024-10-26 @ 9:33 AM
Study NCT ID:
NCT00479518
Status:
COMPLETED
Last Update Posted:
2017-02-27
First Post:
2007-05-25
Brief Title:
Prognostic Value of Cardiac and Renal Markers in Ischemic Stroke and Transient Ischemic Attack
Sponsor:
University Hospital Tours
Organization:
University Hospital Tours
Study Overview
Official Title:
Prognostic Value of Cardiac and Renal Markers in the Acute Phase of Ischemic Stroke or Transient Ischemic Attack Albuminuria-Brain Natriuretic Peptide-Cystatine C in Stroke
Status:
COMPLETED
Status Verified Date:
2017-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
ABC-AVC
Brief Summary:
Patients with stroke or transient ischemic attack TIA are at high risk of poor outcome recurrence of cardiovascular events or vascular deathUntil now no reliable predictive biological marker could be identified in the acute phase of strokeWe hypothese that in the acute phase of ischemic stroke or TIA the increase of cardiac brain natriuretic peptide BNP or renal markers albuminuria cystatin Cmight predict recurrence of cardiovascular events or vascular death We want to assess which one of these markers has the best prognosis value in a prospective study of 300 stroke patients followed during 3 years
Detailed Description:
Patients with ischemic stroke or TIA will be included in the 48 hours following the onset of symptoms in 3 university hospitalsFor each patient will be collected
1 blood sample for the BNP measure in pgml
1 blood sample for the Cystatin C measure in mgl
2 urinary samples to measure the albuminecreatinine ratio at inclusion and 5 days after the inclusion and to study the variation of albuminuria in microgramsmin
The clinical follow-up will be organized during 3 years The following events will be notified poor outcome defined with the Barthel and Rankin scores recurrence of cardiovascular or cerebrovascular events vascular death
After adjustment on the main clinical prognosis factors we want to determine wich one of these markers has the best prognosis significance and allows to identify in the acute phase the high-risk patients in order to intensify individual treatment and secondary prevention
1 blood sample for the BNP measure in pgml
1 blood sample for the Cystatin C measure in mgl
2 urinary samples to measure the albuminecreatinine ratio at inclusion and 5 days after the inclusion and to study the variation of albuminuria in microgramsmin
The clinical follow-up will be organized during 3 years The following events will be notified poor outcome defined with the Barthel and Rankin scores recurrence of cardiovascular or cerebrovascular events vascular death
After adjustment on the main clinical prognosis factors we want to determine wich one of these markers has the best prognosis significance and allows to identify in the acute phase the high-risk patients in order to intensify individual treatment and secondary prevention
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None